1 Truth and 1 Misconception About How the Election Will Change Healthcare
The past 10 years can tell us a lot about what will happen in healthcare after the November election, and what won't.
Why Europe Is Looking to This Company for a Coronavirus Vaccine
CureVac is using the same messenger RNA approach that Moderna uses. Why is Moderna getting all the headlines?
1 Green Flag for Teladoc's Future
Investors were frightened by the $18.5 billion price tag for Livongo, but they might be missing the most important metric for valuing the company.
Is OPKO Health Stock a Buy?
Despite high-profile agreements to provide coronavirus testing, this small-cap company might not pass the test in the long term.
1 Red Flag for Teladoc's Future
Coronavirus relief packages eliminated restrictions on telemedicine. Growth for the company could hit a roadblock if these barriers are brought back.
Is It Too Late to Buy Livongo Stock?
The fast-growing chronic disease management company is getting swallowed up in one of the largest deals of the year, but it may not be too late to pick up shares.
Can Either of These Little-Known Biotechs Find New Life Fighting Coronavirus?
Two small biotechs collaborated to find a coronavirus vaccine, but one of them may come out way ahead due to its expertise and other partnerships.
Does This Metric Tell Investors All They Need to Know About Gilead Sciences?
The company has stagnated since its revolutionary HIV and hepatitis C drugs were released, and one metric shows why investors should look elsewhere for returns.
Better Coronavirus Stock: AstraZeneca or Johnson & Johnson
These two pharma heavyweights are among the many players racing to get a COVID-19 vaccine approved.
Quidel and OPKO Health Are Scoring With Coronavirus Testing in Sports. Is the Market Missing It?
Successful partnerships with major sports leagues and updated guidance may mean coronavirus testing is here to stay.
Is Amwell Stock a Buy?
The stock has doubled since its hot IPO, but coronavirus-induced trends might not be enough to satisfy investors seeking outsized gains.
1 Reason to Sell Moderna Now
Brisk executive stock sales raise serious questions about why retail investors should buy shares of this coronavirus vaccine developer.
1 Reason to Buy Moderna Now
The company is developing a software for our bodies that could redefine medicine in the years ahead.
Where Will Teladoc Be in 5 Years?
The company should still be a compelling growth stock after the coronavirus, when things go back to normal (we hope). But investors might not care.
Better Buy: AbbVie vs. Johnson & Johnson
Both are large pharmaceutical companies, but these stocks have some huge differences that can help investors pick the better long-term investment.
2 Top Healthcare Stocks to Watch in October
These stocks could share big news this month, loosening the grip of the coronavirus on our lives.
Is Gilead Sciences a Buy?
Investors interested in Gilead Sciences need to look forward, not backward, to avoid the common trap of thinking history will repeat itself.
3 Stocks to Buy No Matter What Happens in November
Forget politics and a pandemic. The outlook for these stocks keeps getting better, and analysts can't keep up.
Forget Snowflake! Buy This Ultra-High-Growth Stock
After doubling sales last year, this vaccine maker is speeding toward a revolution in the way humans prevent disease.
Next Coronavirus Market Correction: Where to Invest $5,000
When you have an opportunity to buy the best stocks on the cheap, don't outsmart yourself.